Oblenio Bio
Lexington, US · 2 known investors
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion. The company aims to achieve long-term drug-free remission in autoimmune disease patients.
BiotechHealthtechMedical Devices
Founders & leadership
ST
Samantha Truexin𝕏CEO of Oblenio BioShe previously served as CEO of Upstream Bio and of Quench Bio, and earlier held operating roles as COO and Head of Corporate Development at Synlogic Therapeutics and Chief Business Officer at Padlock Therapeutics. She chairs the board of Artios and sits on the board of Avalo Therapeutics, where she chairs the nominating and governance committee, following earlier board service at HotSpot Therapeutics.
Investors · 2
Funding
SEC filings, press & company announcements$62M disclosed across 1 round · 2026
- $62MSeries BJun 2026 · 7 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 8
by search overlapbio5 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
iBio5 shared keywordsiBio discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies against hard-to-drug targets. The company operates in the biotech and drug discovery space.
bioio4 shared keywordsBIOIO develops a genetics-based platform for elucidating drug mechanisms of action, combining decades of research in pharmacology with big data and automation to accelerate drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to understand how drugs work.
Primrose Bio4 shared keywords
Bridgebio4 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
IQVIA4 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Indiebio3 shared keywordsIndieBio was a startup accelerator and pre-seed investment program launched by SOSV in San Francisco in 2015, providing on-site bio-labs and funding to science founders across biotech, food, agriculture, industrial decarbonization, AI, therapeutics, and diagnostics. As of 2026 the program was rebranded to SOSV NY and SOSV SF, expanding its focus from bio to broader deep tech.
Sanegene Bio3 shared keywordsSanegeneBio is a biotech company developing RNA interference (RNAi) genetic medicines for obesity, cardiometabolic, and autoimmune diseases. Its LEAD (Ligand and Enhancer Assisted Delivery) platform enables tissue-specific gene silencing in the liver, adipose tissue, muscle, and immune cells via subcutaneous dosing.
Companies competing with Oblenio Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Oblenio Bio do?
- Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion. The company aims to achieve long-term drug-free remission in autoimmune disease patients.
- Who are Oblenio Bio's investors?
- Oblenio Bio's investors include Aditum Bio, GV (Google Ventures).
- How much funding has Oblenio Bio raised?
- Oblenio Bio has disclosed $62M raised across 1 round.
- Where is Oblenio Bio headquartered?
- Oblenio Bio is headquartered in Lexington, US.